Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome

No abstract is available for this paper.

• Publication year

  2016

• Venue

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijgo.2015.06.065PMID 26613823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: A randomized study

  2013cited by this paper
• The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism.

  2012cited by this paper
• Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.

  2012cited by this paper
• Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study.

  2012cited by this paper
• Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese women.

  2011cited by this paper
• Oral Contraceptives in Polycystic Ovary Syndrome: Risk-Benefit Assessment

  2008cited by this paper
• Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism

  2007cited by this paper
• Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

  2006cited by this paper
• Exogenous sex hormones and thrombophilia.

  2006cited by this paper
• Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.

  2005cited by this paper
• Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.

  2005cited by this paper
• Rook's Textbook of Dermatology

  2004cited by this paper
• A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.

  2004cited by this paper
• An observational study of Yasmin® in the management of women with polycystic ovary syndrome

  2004cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

  2004cited by this paper
• Polycystic ovary syndrome in adolescence--a therapeutic conundrum.

  2004cited by this paper
• Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome.

  2004cited by this paper
• A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.

  2003cited by this paper
• Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.

  2003cited by this paper
• Polycystic ovary syndrome. A diagnostic challenge.

  2001cited by this paper
• Biological coagulation findings in third-generation oral contraceptives.

  1999cited by this paper
• Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

  1999cited by this paper
• Triglyceride, high density lipoprotein, and coronary heart disease.

  1993cited by this paper
• Clinical gynecologic endocrinology and infertility

  1991cited by this paper
• [Disorders of the hair].

  1974cited by this paper

• Pharmacological and Non-Pharmacological Interventions for Polycystic Ovary Syndrome (PCOS) in Indian Women: A Systematic Review and Meta-Analysis

  2025cites this paper
• Effects of estetrol/drospirenone versus ethinyl estradiol/drospirenone on glucose tolerance in women with polycystic ovary syndrome: A randomised controlled trial

  2025cites this paper
• Continuous wavelet transform and integration of discrete wavelet transform with principal component analysis and fuzzy inference system for the simultaneous determination of ethinyl estradiol and drospirenone in combined oral contraceptives.

  2024cites this paper
• Combined oral contraceptive use and obesity in women with polycystic ovary syndrome. A meta-analysis of randomized clinical trials

  2024cites this paper
• Randomized control trial to compare effects of ultra-low dose (Ethinylestradiol 20 μg or 15 μg) with low dose (Ethinylestradiol 30 μg) hormonal pills on lipid discordance in non-obese PCOS women

  2023cites this paper
• Different kinds of oral contraceptive pills in polycystic ovary syndrome: A systematic review and meta-analysis.

  2023cites this paper
• Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials

  2022cites this paper
• The influence of combined oral contraceptive pills on carbohydrate metabolism in healthy women and in women with PCOS - a systemic review

  2022cites this paper
• Influence of combined oral contraceptives on polycystic ovarian morphology-related parameters in Korean women with polycystic ovary syndrome

  2019cites this paper
• Managing Women’s Hyperandrogenism

  2019cites this paper
• Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)

  2019cites this paper
• Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India

  2019cites this paper
• Therapeutic non-contraceptive properties of the drug containing ethinylestradiol 0.03 mg and drospirenone 3 mg

  2019cites this paper
• Treatments

  2018cites this paper
• FSRH Guideline (January 2019) Combined Hormonal Contraception

  2018cites this paper
• Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

  2017cites this paper
• Voltammetric Determination of Drospirenone on Mercury Film Electrode

  2017cites this paper
• Polycystic ovary syndrome throughout a woman’s life

  2017cites this paper
• New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome

  2017cites this paper
• Endocrine disorders and hormonal therapy for adolescent acne

  2017cites this paper
• Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

  2017influential citation
• Good clinical practice recommendations on management of infertility in patients from India with polycystic ovary syndrome

  2015cites this paper